<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2341">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05130684</url>
  </required_header>
  <id_info>
    <org_study_id>202005115MIPB</org_study_id>
    <nct_id>NCT05130684</nct_id>
  </id_info>
  <brief_title>Neo-NTP-CRT for Locally Advanced ESCC</brief_title>
  <acronym>Neo-NTP-CRT</acronym>
  <official_title>Neoadjuvant Nivolumab Plus Paclitaxel/ Cisplatin- Chemo- Radiotherapy (Neo-NTP-CRT) Followed by Esophagectomy for Locally Advanced Esophageal Squamous Cell Carcinoma (ESCC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Taiwan University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Taiwan University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators hypothesize that nivolumab combined with neoadjuvant chemoradiotherapy&#xD;
      (CRT) is safe and effective in patients with locally advanced esophageal squamous cell&#xD;
      carcinoma (LAESCC).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 22, 2021</start_date>
  <completion_date type="Anticipated">March 1, 2024</completion_date>
  <primary_completion_date type="Anticipated">March 1, 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>change in treatment related death</measure>
    <time_frame>30 days</time_frame>
    <description>no increase of treatment-related death within 30 days after esophagectomy</description>
  </primary_outcome>
  <primary_outcome>
    <measure>rate of completion of protocol treatment</measure>
    <time_frame>5 months</time_frame>
    <description>successful completion of preoperative therapy and processing to surgery without any extended treatment-related delay, which is defined as &gt; 19 weeks after the first dose of nivolumab (d-14) in neo-NTP-CRT (19 weeks include 15 weeks of protocol treatment plus 4 weeks of flexibility.).</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">43</enrollment>
  <condition>Locally Advanced Esophageal Squamous Cell Carcinoma</condition>
  <arm_group>
    <arm_group_label>Neo-CRT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Nivolumab 240 mg, 30-min IVF, Q2W on days -14, 1, 15, and 29;&#xD;
Paclitaxel 50 mg/m2, 1h-IVF, on days 1, 8, 15, 22, and 29;&#xD;
Cisplatin 30 mg/m2,1h-IVF,on days 1, 8,15, 22, and 29;&#xD;
RT: 1.8 Gy/fraction, 5 days a week, for 25 fractions (total dose= 45 Gy).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nivolumab</intervention_name>
    <description>adding nivolumab to conventional neoadjuvant CRT</description>
    <arm_group_label>Neo-CRT</arm_group_label>
    <other_name>paclitaxel</other_name>
    <other_name>cisplatin</other_name>
    <other_name>radiation</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Pathologically proven squamous cell carcinoma of the intrathoracic esophagus.&#xD;
&#xD;
          2. Locally advanced disease, which is defined by the TNM system of the American Joint&#xD;
             Committee on Cancer (AJCC) Cancer Staging System (8th edition), fulfilling one of the&#xD;
             following criteria as determined by endoscopic ultrasound, computed tomography,&#xD;
             bronchoscopy and positron emission tomography:&#xD;
&#xD;
               1. cT3/4a, N0, M0;&#xD;
&#xD;
               2. cT1-3, N1-3, M0.&#xD;
&#xD;
          3. Tumor length longitudinal ≤ 8cm and radial ≤ 5cm.&#xD;
&#xD;
          4. The tumor must not extend more than 2cm into the stomach.&#xD;
&#xD;
          5. No invasion of the tracheobronchial tree or presence of tracheoesophageal fistula.&#xD;
&#xD;
          6. Age ≥ 20 and ≤ 75 years old.&#xD;
&#xD;
          7. Performance status ECOG 0~1.&#xD;
&#xD;
          8. Adequate bone marrow reserves, defined as:&#xD;
&#xD;
               1. white blood cells (WBC) ≥ 4,000/µl or neutrophil count (ANC) ≥ 2,000/µl;&#xD;
&#xD;
               2. platelets ≥ 100,000/µl.&#xD;
&#xD;
          9. Adequate liver function reserves, defined as:&#xD;
&#xD;
               1. hepatic transaminases ≤ 2.5 x upper limit of normal (ULN);&#xD;
&#xD;
               2. serum total bilirubin ≤ 2.0 x upper limit of normal (ULN).&#xD;
&#xD;
         10. Adequate renal function: Creatinine ≤1.5 x upper normal limit or estimated creatinine&#xD;
             clearance ≥ 50 ml/min (estimated by Cockcroft-Gault formulation)&#xD;
&#xD;
         11. Written informed consent.&#xD;
&#xD;
         12. Female subject of childbearing potential should have a negative urine or serum&#xD;
             pregnancy within 72 hours prior to receiving the first dose of study medication. If&#xD;
             the urine test is positive or cannot be confirmed as negative, a serum pregnancy test&#xD;
             will be required.&#xD;
&#xD;
         13. Female subjects of childbearing potential must be willing to use an adequate method of&#xD;
             contraception as outlined in Section - Contraception, for the course of the study&#xD;
             through 120 days after the last dose of study medication.&#xD;
&#xD;
             Note: Abstinence is acceptable if this is the usual lifestyle and preferred&#xD;
             contraception for the subject.&#xD;
&#xD;
         14. Male subjects of childbearing potential must agree to use an adequate method of&#xD;
             contraception as outlined in Section - Contraception, starting with the first dose of&#xD;
             study therapy through 120 days after the last dose of study therapy.&#xD;
&#xD;
        Note: Abstinence is acceptable if this is the usual lifestyle and preferred contraception&#xD;
        for the subject.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Adenocarcinoma.&#xD;
&#xD;
          2. Previous thoracic irradiation.&#xD;
&#xD;
          3. Previous systemic chemotherapy&#xD;
&#xD;
          4. Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent.&#xD;
&#xD;
          5. Synchronously diagnosed squamous cell carcinoma of aerodigestive way, other than&#xD;
             esophageal cancer.&#xD;
&#xD;
          6. Prior malignancy, except for the following:&#xD;
&#xD;
               1. adequately treated basal cell or squamous cell skin cancer;&#xD;
&#xD;
               2. in-situ cervical cancer;&#xD;
&#xD;
               3. a &quot;cured&quot; malignancy more than 5 years prior to enrollment.&#xD;
&#xD;
          7. Significant co-morbid disease, which prohibits the conduction of chemotherapy,&#xD;
             concurrent chemo- radiotherapy, or radical surgery, such as active systemic infection,&#xD;
             symptomatic cardiac or pulmonary disease, or psychiatric disorders.&#xD;
&#xD;
          8. Documented myocardial infarction within the 6 months preceding registration&#xD;
             (pretreatment ECG evidence of infarct only will not exclude patients). Patients with a&#xD;
             history of significant ventricular arrhythmia requiring medication. Patients with a&#xD;
             history of 2nd or 3rd degree heart block.&#xD;
&#xD;
          9. Pre-existing motor or sensory neurotoxicity greater than grade 1.&#xD;
&#xD;
         10. Patients with prior allergic reactions to drug containing Cremophor, such as&#xD;
             teniposide or cyclosporine.&#xD;
&#xD;
         11. Weight loss &gt; 15%.&#xD;
&#xD;
         12. Dementia or altered mental status that would prohibit the understanding and completion&#xD;
             of informed consent.&#xD;
&#xD;
         13. Estimated life expectancy less than 3 months.&#xD;
&#xD;
         14. Has a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any&#xD;
             other form of immunosuppressive therapy within 7 days prior to the first dose of trial&#xD;
             treatment.&#xD;
&#xD;
         15. Has a known history of active TB (Bacillus Tuberculosis)&#xD;
&#xD;
         16. Has active autoimmune disease that has required systemic treatment in the past 2 years&#xD;
             (i.e. with use of disease modifying agents, corticosteroids or immunosuppressive&#xD;
             drugs). Replacement therapy (eg., thyroxine, insulin, or physiologic corticosteroid&#xD;
             replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a&#xD;
             form of systemic treatment.&#xD;
&#xD;
         17. Has known history of, or any evidence of active, non-infectious pneumonitis,&#xD;
             interstitial lung disease or pulmonary fibrosis.&#xD;
&#xD;
         18. Concurrent diverticulitis or symptomatic gastrointestinal ulcerative disease.&#xD;
&#xD;
         19. Is pregnant or breastfeeding, or expecting to conceive or father children within the&#xD;
             projected duration of the trial, starting with the pre-screening or screening visit&#xD;
             through 120 days after the last dose of trial treatment.&#xD;
&#xD;
         20. Has a known history of Human Immunodeficiency Virus (HIV) (HIV 1/2 antibodies).&#xD;
&#xD;
         21. Has known active Hepatitis B (e.g., HBsAg reactive) or Hepatitis C (e.g., anti-HCV&#xD;
             reactive and HCV RNA [qualitative] are detected).&#xD;
&#xD;
         22. Patients with a negative HBs antigen test but a positive test result for either HBs&#xD;
             antibody or HBc antibody with a detectable level of HBV-DNA.&#xD;
&#xD;
         23. Has received a live vaccine within 30 days of planned start of study therapy. Note:&#xD;
             Seasonal influenza vaccines for injection are generally inactivated flu vaccines and&#xD;
             are allowed; however intranasal influenza vaccines (e.g., Flu-Mist®) are live&#xD;
             attenuated vaccines, and are not allowed.&#xD;
&#xD;
         24. Has received organ transplantation.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chih-Hung Hsu, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Taiwan University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ta-Chen Huang, MD</last_name>
    <phone>+886223123456</phone>
    <phone_ext>71669</phone_ext>
    <email>e360215@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>National Taiwan University Hospital</name>
      <address>
        <city>Taipei</city>
        <zip>100</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ta-Chen Huang, MD</last_name>
      <phone>+886223123456</phone>
      <phone_ext>71669</phone_ext>
      <email>e360215@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>October 24, 2021</study_first_submitted>
  <study_first_submitted_qc>November 22, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 23, 2021</study_first_posted>
  <last_update_submitted>November 22, 2021</last_update_submitted>
  <last_update_submitted_qc>November 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
    <mesh_term>Esophageal Squamous Cell Carcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Nivolumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

